tm logo
AZULTIS
Live/Pending
PUBLISHED FOR OPPOSITION

on 17 Sep 2024

Last Applicant/ Owned by

22 rue Marc Donadille

Marseille

FR

13013

Serial Number

97877494 filed on 07th Apr 2023

Registration Number

N/A

Correspondent Address

Kaitlyn M. Garvin

Kaitlyn M. Garvin SAUNDERS & SILVERSTEIN LLP

AMESBURY, MA 01913

United States

Filing Basis

No Filing Basis

Disclaimer

NO DATA

AZULTIS

Pharmaceutical preparations for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestivesystem by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification ofgynecological and urological systems by instillation, injection or local application; chemical preparations for medical use formarking Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestivesystem by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification ofgynecological and urological systems by instillation, injection or local application; chemical preparations for medical use formarking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectableadministration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urologicalsystems by instillation, injection or local application; injectable pharmaceutical solutions for use as a marker during gastrointestinal endoscopy; injectable pharmaceutical solutions used as a contrast solution for medical imaging procedures; injectablepharmaceutical solutions for medical diagnostic purposes for viewing and marking tissue; injectable pharmaceutical solutionsused as an aid in visualization of topographic irregularities and in delineation of polypoid or flat lesions, including adenomas;injectable pharmaceutical solutions used for polyps or lesions resection medicines for tissue staining; injectable pharmaceuticalsolutions for use as a marker during visceral surgery; injectable pharmaceutical solutions for the detection of amniotic fluid leaks;injectable pharmaceutical solutions for use as a marker during cystoscopy and ureteral catheterization; injectable pharmaceuticalsolutions for use as a marker during vessel delineation and tumor localization procedures; clinical medical reagents; syntheticpeptides for pharmaceutical use, namely, for cancer treatments, immunotherapy, cell therapy, antivirals and antibiotics;phytotherapy preparations for medical use; diagnostic preparations in vials for medical use; drug delivery agents in the form ofinjectable compounds being pharmaceutical solutions in pre-filled vials that facilitate the delivery of pharmaceutical preparations;pre-filled syringes for medical and clinical purposes, sold filled with injectable pharmaceutical solutions for marking tissue byinjection application in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable, for theantiseptic treatment orally or topically, for marking and functional verification gynecological and urological systems, by instillation,injection or local application


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 97877494

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 360.502.11

44D Filed

Yes

44D Current

No

44E filed

No

44E Current

Yes

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
17th Sep 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17th Sep 2024PUBLISHED FOR OPPOSITION
28th Aug 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12th Aug 2024APPROVED FOR PUB - PRINCIPAL REGISTER
11th Aug 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
11th Aug 2024TEAS/EMAIL CORRESPONDENCE ENTERED
10th Aug 2024ASSIGNED TO LIE
23rd Feb 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
16th Jan 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
16th Jan 2024NON-FINAL ACTION E-MAILED